论文部分内容阅读
目的:观察灯盏花素注射液治疗急性眩晕的疗效。方法:80例患者以随机数字法随机分为对照组和治疗组各40例,对照组仅给予苯海拉明20 mg im;治疗组再对照组治疗基础上加用灯盏花素注射液40 mg加入5%葡萄糖注射液250 ml,ivd。3 d后比较两组起效时间、眩晕评分、临床疗效及不良反应等。结果:治疗组起效明显快于对照组(P<0.05);两组治疗后眩晕评分分别为(4.47±0.72)和(3.82±0.63),差异有统计学意义(P<0.05);治疗组总有效率为95.0%,高于对照组的80.0%(P<0.05);治疗中无明显不良反应发生。结论:灯盏花素注射液辅助治疗急性眩晕起效快,安全有效,值得临床推广。
Objective: To observe the efficacy of breviscapine injection in the treatment of acute vertigo. Methods: Eighty patients were randomly divided into control group and treatment group with 40 cases in each group. The control group was given diphenhydramine 20 mg im only. The treatment group and the control group were treated with breviscapine injection 40 mg Add 5% glucose injection 250 ml, ivd. After 3 days, the onset time, vertigo score, clinical efficacy and adverse reactions of the two groups were compared. Results: The treatment group was significantly faster than the control group (P <0.05). The post-treatment vertigo scores of the two groups were (4.47 ± 0.72) and (3.82 ± 0.63) respectively, with statistical significance (P <0.05) The total effective rate was 95.0%, which was higher than that of the control group (80.0%, P <0.05). No adverse reactions occurred during the treatment. Conclusion: Breviscapine injection adjuvant treatment of acute dizziness rapid onset, safe and effective, worthy of clinical promotion.